SUTENT

Phase 2Small molecule

Pfizer

SUTENT is one of 266 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

265

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Brain CancerActive, not recruiting

Metastatic MelanomaActive, not recruiting

Breast CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Gastrointestinal Stromal TumorActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Kidney CancerPreclinical

Active, not recruiting

Brain CancerPhase 2

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Renal Cell CarcinomaPreclinical

Active, not recruiting

Gastrointestinal Stromal TumorPreclinical

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

SUTENT

Pfizer

Phase 2

1 2

Zinecard

CChildren's Oncology Group

Preclinical

2 3

Chantix

PPrism Pharmaceuticals

Preclinical

1 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 7

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Lipegfilgrastim

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Cell Carcinoma2 trials

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Approved for marketing· Pfizer logo

Pfizer··NCT00130897

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Completed· Pfizer logo

Pfizer··NCT00684645·186 enrolled

Small Cell Lung Cancer1 trial

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Completed·UUS Oncology Research·Phase 2·NCT00864721·63 enrolled

Fibrolamellar Carcinoma1 trial

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01215565·4 enrolled

Urothelial Carcinoma1 trial

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00393796·54 enrolled

Gastrointestinal Stromal Tumor1 trial

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Approved for marketing· Pfizer logo

Pfizer··NCT00094029

5 more indications

Kidney Cancer1 trial

Study In Patients With Kidney Cancer Treated With Sutent

Completed· Pfizer logo

Pfizer··NCT00873210·121 enrolled

Breast Cancer1 trial

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Terminated·BBaylor Breast Care Center·Phase 1/2·NCT00905021·4 enrolled

Biomarkers1 trial

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01215578·33 enrolled

Metastatic Melanoma1 trial

Clinical Trial of Sutent to Treat Metastatic Melanoma

Completed·—·Phase 2·NCT00631618·12 enrolled

Brain Cancer1 trial

Sunitinib to Treat Recurrent Brain Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00923117·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for SUTENT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SUTENT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SUTENT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

SUTENT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Cell Carcinoma2 trials

Small Cell Lung Cancer1 trial

Fibrolamellar Carcinoma1 trial

Urothelial Carcinoma1 trial

Gastrointestinal Stromal Tumor1 trial

Kidney Cancer1 trial

Breast Cancer1 trial

Biomarkers1 trial

Metastatic Melanoma1 trial

Brain Cancer1 trial

References

Drug Info

Quick Facts

Related News